Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Steven G. DuBois"'
Publikováno v:
Eur J Cancer
AIM: The lag time between initial human studies of oncology agents to the first-in-child clinical trials of these agents has not been defined. METHODS: We conducted a systematic analysis of time from first-in-human trials to first-in-child trials (ag
Autor:
Katherine K. Matthay, John Neuhaus, Stephanie Fetzko, Kieuhoa T. Vo, Vandana Batra, Araz Marachelian, Brian Weiss, Steven G. DuBois, John M. Maris, Kelly E. Huibregtse, Greg Yanik
Publikováno v:
European journal of cancer (Oxford, England : 1990). 66
Several reports of second malignant neoplasm (SMN) in patients with relapsed neuroblastoma after treatment with (131)I-MIBG suggest the possibility of increased risk. Incidence of and risk factors for SMN after (131)I-MIBG have not been defined. This
Autor:
Didier Frappaz, Steven G. DuBois, Ryan Geschwindt, Lia Gore, Robert Iannone, Arne van Schanke, Birgit Geoerger, Sara M. Federico, Isabelle Aerts, Margaret E. Macy, Andrew D.J. Pearson, Rui Wang
Publikováno v:
European journal of cancer (Oxford, England : 1990). 62
Aim Dalotuzumab is a highly specific, humanised immunoglobulin G1 monoclonal antibody against insulin-like growth factor receptor 1. This multicenter phase 1 study (NCT01431547) explored the safety and pharmacokinetics of dalotuzumab monotherapy (par